3/5
04:01 pm
crvs
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Neutral
Report
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
2/23
04:37 pm
crvs
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/23
04:01 pm
crvs
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/16
07:38 pm
crvs
Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price Surge [Yahoo! Finance]
Medium
Report
Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price Surge [Yahoo! Finance]
1/29
08:03 am
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $30.00 price target on by analysts at Mizuho.
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $30.00 price target on by analysts at Mizuho.
1/27
01:42 pm
crvs
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know [Yahoo! Finance]
Low
Report
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know [Yahoo! Finance]
1/25
08:01 pm
crvs
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study [Yahoo! Finance]
1/24
03:28 pm
crvs
Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans [Yahoo! Finance]
Medium
Report
Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans [Yahoo! Finance]
1/23
05:00 pm
crvs
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
Medium
Report
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
1/22
01:06 pm
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
1/22
01:11 am
crvs
Corvus Pharmaceuticals rises 5%, prices $175M stock offering at $22.15 [Seeking Alpha]
Medium
Report
Corvus Pharmaceuticals rises 5%, prices $175M stock offering at $22.15 [Seeking Alpha]
1/21
10:53 pm
crvs
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Medium
Report
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
1/21
02:51 pm
crvs
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon [Seeking Alpha]
Medium
Report
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon [Seeking Alpha]
1/21
11:44 am
crvs
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know [Seeking Alpha]
Low
Report
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know [Seeking Alpha]
1/21
10:11 am
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $32.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $32.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.
1/20
04:06 pm
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
1/20
04:01 pm
crvs
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
1/20
02:02 pm
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $20.00 price target on by analysts at Mizuho.
Medium
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $20.00 price target on by analysts at Mizuho.
1/20
12:05 pm
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/20
07:00 am
crvs
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
High
Report
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
1/16
04:01 pm
crvs
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
High
Report
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
1/12
07:05 am
crvs
Retail investors account for 39% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while institutions account for 39% [Yahoo! Finance]
Low
Report
Retail investors account for 39% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while institutions account for 39% [Yahoo! Finance]
1/5
09:15 am
crvs
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference [Yahoo! Finance]
1/5
08:30 am
crvs
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
Medium
Report
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
12/11
10:04 am
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.